These can be designed to target tumor-associated antigens, thereby minimizing damage to healthy tissues and reducing off-target effects (173).CRPC is enriched with our-associated antigens, including, but not limited to, PSMA, PSCA, hK2, and STEAP1 (174). The gene discussed is FOLH1; the disease is neoplasm.